Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-12 (canceled).

Claim 13 (currently amended): A purified monoclonal antibody which specifically recognizes a peptide consisting of ~~having~~ the amino acid sequence of SEQ ID NO:2.

Claim 14 (canceled).

Claim 15 (currently amended): A therapeutic composition for increasing the concentration of antibodies to aglycoprotein 10B antigenic epitopes ~~antimalignin antibody concentration~~ in a patient in need thereof, the composition comprising a peptide selected from the group consisting of the peptide consisting of SEQ ID NO:1, the peptide consisting of SEQ ID NO:2, and combinations thereof.

Claim 16-23 (canceled).

Claim 24 (currently amended): A kit for determining the concentration of aglycoprotein 10B antigenic epitopes present in blood of a patient comprising at least one blood collection tube or pipette and a purified monoclonal [[an]] antibody that specifically recognizes the peptide consisting of SEQ ID NO:1 or the peptide consisting of SEQ ID NO:2 wherein said antibody is coated on the inner surface of said collection tube or pipette.

Claim 25 (currently amended): A kit for determining the concentration of aglycoprotein 10B antigenic epitopes ~~anti-malignin antibody~~ present in blood of a patient comprising at least one blood collection tube or pipette and a peptide consisting of ~~having~~ the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 26 (previously presented): The kit of claim 25 wherein the peptide is coated on the inner surface of the tube or pipette.

Claim 27 (currently amended): An isolated nucleic acid encoding a peptide ~~comprising~~ consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claims 28-31 (canceled).